AXGNAxogen, Inc.
Price
+110%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, demanding price, growth steady, the market undecided.
We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries. We provide innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Axogen, Inc. (AXGN) reported revenue of $70M in Q2 2026 (quarter ended Jun 30, 2026), up 23% from the same quarter a year earlier. That came with a gross margin of 73% and net loss of $1.5M. For the full year FY2025, revenue was $225M (+20% year on year) and net income −$16M. Its largest region in Q2 2026 was United States at $69M, 99% of the disclosed total, well ahead of Non Us at 1.0%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair.Regulation FD disclosure · press release
- Sep 10, 2026The information contained in.Material agreement entered · Form 8-K/A
- Sep 10, 2026Merger Agreement On September 9, 2026, Axogen, Inc., a Minnesota corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Omega Merger Sub, Inc., a Georgia corporation and wholly owned subsidiary of the Company (“Merger Sub”), BioCircuit Technologies, Inc., a Georgia …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $69.7MThe company’s own SEC segment disclosure.
- United States$69.0M99%
- Non Us$726.0K1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.